Endothelin Receptor Antagonism in Proteinuric Nephropathy
Status:
Completed
Trial end date:
2007-12-01
Target enrollment:
Participant gender:
Summary
The number of people with kidney problems is increasing rapidly, related in part to the
increasing prevalence of diabetes. Patients with kidney problems tend to have protein leaking
into the urine (proteinuria). Both proteinuria and the kidney disease itself are associated
with an increased risk of heart disease. Reducing proteinuria is an important treatment goal
in people with kidney problems. Endothelin is a chemical produced both by blood vessels and
the kidney. Higher than normal levels of endothelin are thought to contribute to progression
of kidney disease and proteinuria. By using drugs that block the effects of endothelin
('endothelin receptor antagonists') we can hopefully reduce both of these. The purpose of the
study is to ascertain whether endothelin receptor antagonists improve kidney function and
reduce proteinuria more so than other commonly used drugs.
Phase:
Phase 1
Details
Lead Sponsor:
University of Edinburgh
Collaborator:
British Heart Foundation
Treatments:
cyclo(Trp-Asp-Pro-Val-Leu) Endothelin A Receptor Antagonists Nifedipine